AV5124 Influenza Virus Replication Inhibitor

ChemDiv Inc., dedicated to partnering in discovery and development of breakthrough therapies based on its unique chem-bio platforms, announces successful completion of Phase I clinical trials for AV5124, an innovative influenza virus replication inhibitor being developed by Viriom Inc. (Viriom).

AV5124 is an extremely effective inhibitor of influenza virus RNA processing that is potent against all tested influenza types including viruses resistant to neuraminidase inhibitors (Tamiflu®) or cap-dependent endonuclease inhibitors (Xofluza®). Together, Viriom and ChemDiv showcase AV5124’s potent suppression of diverse Influenza A and Influenza B viruses, including drug-resistant variants and highly pathogenic avian influenza strains.

The completion of Phase I clinical trials stands as a testament to AV5124’s remarkable safety and tolerability. Blood drug levels achieved in the study indicate sustained and potent virus suppression over several days, marking a significant milestone in the pursuit of an effective therapy for seasonal or pandemic influenza.